{"nctId":"NCT02285114","briefTitle":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","startDateStruct":{"date":"2015-01-20","type":"ACTUAL"},"conditions":["HIV-1"],"count":41,"armGroups":[{"label":"F/TAF+3rd ARV Agent (Cohort 1)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 1)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: Boosted PIs"]},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 2)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"FTC/TAF+3rd ARV Agent (Cohort 3, Part A)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"FTC/TAF+3rd ARV Agent (Cohort 4, Part A)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part B - Group 1)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"F/TAF+3rd ARV Agent (Cohort 2, Part B - Group 2)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"FTC/TAF+3rd ARV Agent (Cohort 3, Part B)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"FTC/TAF+3rd ARV Agent (Cohort 4, Part B)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]},{"label":"FTC/TAF+3rd ARV Agent (Extension Phase)","type":"EXPERIMENTAL","interventionNames":["Drug: F/TAF","Drug: 3rd ARV agent"]}],"interventions":[{"name":"F/TAF","otherNames":[]},{"name":"3rd ARV agent","otherNames":[]},{"name":"Boosted PIs","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Human immunodeficiency virus 1 (HIV-1) infected male and female adolescents and children aged 1 month to \\< 18 years at baseline/Day 1 (according to requirements of the enrolling cohort)\n* Must be able to give written assent prior to any screening evaluations\n* Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements\n* Body weight at screening as follows:\n\n  * Cohort 1: ≥ 35 kg\n  * Cohort 2, Group 1: ≥ 25 kg\n  * Cohort 2, Group 2: 17 kg to \\< 25 kg\n  * Cohort 3: to be updated per a protocol amendment\n  * Cohort 4: to be updated per a protocol amendment\n* Currently on a stable 2-nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) containing regimen that includes a 3rd antiretroviral (ARV) agent for ≥ 6 consecutive months prior to screening\n* Plasma HIV-1 ribonucleic acid (RNA) levels \\< 50 copies/mL for ≥ 6 consecutive months preceding the screening visit\n* No opportunistic infection within 30 days of study entry (at baseline/Day 1)\n* A negative serum β-human chorionic gonadotropin (HCG) pregnancy test is required for females of childbearing potential only\n\nKey Exclusion Criteria:\n\n* An acquired immunodeficiency syndrome (AIDS) - indicator condition with onset within 30 days prior to screening\n* Life expectancy of \\< 2 years\n* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline/Day 1\n* Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit\n* Active hepatitis C virus (HCV) infection defined as positive for HCV antibody and having detectable HCV RNA\n* Positive hepatitis B surface antigen or other evidence of active hepatitis B virus (HBV) infection.\n* Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, or compliance with the protocol.\n* Pregnant or lactating females\n* Have history of significant drug sensitivity or drug allergy\n* Have previously participated in an investigational trial involving administration of any investigational agent, other than TDF, within 30 days prior to the study dosing\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacokinetic (PK) Parameter (Cohort 1): AUCtau of Tenofovir Alafenamide (TAF)","description":"AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139.9","spread":"113.23"},{"groupId":"OG001","value":"200.6","spread":"83.80"}]}]}]},{"type":"PRIMARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): AUCtau of TAF","description":"AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210.8","spread":"97.35"},{"groupId":"OG001","value":"220.2","spread":"187.96"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Week 24","description":"An AE is any untoward medical occurrence in a clinical study participant which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The TEAEs were defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): Cmax of TAF, FTC, and TFV","description":"Cmax is defined as the maximum concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":"77.63"},{"groupId":"OG001","value":"139.3","spread":"76.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2259.2","spread":"470.75"},{"groupId":"OG001","value":"2320.0","spread":"482.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":"4.89"},{"groupId":"OG001","value":"11.6","spread":"2.74"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): Cmax of TAF, FTC, and TFV","description":"Cmax is defined as the maximum concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.4","spread":"264.70"},{"groupId":"OG001","value":"232.0","spread":"253.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2074.4","spread":"565.91"},{"groupId":"OG001","value":"2020.0","spread":"1151.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":"19.20"},{"groupId":"OG001","value":"48.1","spread":"8.07"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): Clast of TAF","description":"Clast is defined as the last observable concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.98"},{"groupId":"OG001","value":"5.5","spread":"3.76"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): Clast of TAF","description":"Clast is defined as the last observable concentration of drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.32"},{"groupId":"OG001","value":"2.1","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): CL/F of TAF","description":"CL/F is defined as the apparent clearance following oral administration of the drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129.8","spread":"101.67"},{"groupId":"OG001","value":"143.4","spread":"53.55"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): CL/F of TAF","description":"CL/F is defined as the apparent clearance following oral administration of the drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174.3","spread":"156.75"},{"groupId":"OG001","value":"102.1","spread":"60.75"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): Vz/F of TAF","description":"Vz/F is defined as the apparent volume of distribution of the drug following oral administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":"60.68"},{"groupId":"OG001","value":"95.3","spread":"43.47"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): Vz/F of TAF","description":"Vz/F is defined as the apparent volume of distribution of the drug following oral administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.8","spread":"145.57"},{"groupId":"OG001","value":"63.1","spread":"63.39"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): AUCtau of FTC and TFV","description":"AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14769.9","spread":"4481.23"},{"groupId":"OG001","value":"14339.8","spread":"6099.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"415.5","spread":"105.92"},{"groupId":"OG001","value":"193.2","spread":"46.73"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): AUCtau of FTC and TFV","description":"AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12360.8","spread":"2928.36"},{"groupId":"OG001","value":"11171.7","spread":"2921.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"999.4","spread":"409.33"},{"groupId":"OG001","value":"908.2","spread":"90.62"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 1): Ctau of FTC and TFV","description":"Ctau is defined as the observed drug concentration at the end of the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223.4","spread":"482.59"},{"groupId":"OG001","value":"301.7","spread":"624.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"4.11"},{"groupId":"OG001","value":"6.7","spread":"3.00"}]}]}]},{"type":"SECONDARY","title":"PK Parameter (Cohort 2: Part A - Groups 1 and 2): Ctau of FTC and TFV","description":"Ctau is defined as the observed drug concentration at the end of the dosing interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.4","spread":"22.71"},{"groupId":"OG001","value":"75.4","spread":"27.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"16.39"},{"groupId":"OG001","value":"30.9","spread":"3.53"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing TEAEs and SAEs Through Week 48","description":"An AE is any untoward medical occurrence in a clinical study participant which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The TEAEs were defined as any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"77.8","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24, as Defined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48, as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"77.8","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-130","spread":"272.6"},{"groupId":"OG001","value":"68","spread":"352.5"},{"groupId":"OG002","value":"-299","spread":"48.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-105","spread":"162.9"},{"groupId":"OG001","value":"210","spread":"406.5"},{"groupId":"OG002","value":"-124","spread":"37.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"3.840"},{"groupId":"OG001","value":"1.29","spread":"2.395"},{"groupId":"OG002","value":"0.60","spread":"5.798"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Percentage at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"3.407"},{"groupId":"OG001","value":"0.70","spread":"3.520"},{"groupId":"OG002","value":"3.65","spread":"7.283"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Palatability of F/TAF Formulation","description":"Palatability was reported based on the pleasant product taste as 'Yes' or 'No'. Data has been reported for Participant Response (PR) and Guardian Response (GR). Participants with missing data were reported as N/A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Acceptability of F/TAF Formulation","description":"Acceptability has been reported for categories medication size, shape and difficulty swallowing as 'Yes' or 'No' for Participant Response (PR) and Guardian Response (GR). Participants with missing data were reported as N/A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":28},"commonTop":["Nasopharyngitis","Headache","Influenza","Acne","Vomiting"]}}}